Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 5/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | LAP3 | P28838 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12420361 | 1.00 | SLC7A5 (0.50) | SLC7A5ALDH1A1MAPTPTGS1DPP4 | |
| SCHEMBL14884433 | 1.00 | SLC7A5 (0.50) | SLC7A5ALDH1A1MAPTPTGS1DPP4 | |
| SCHEMBL24996455 | 0.84 | SLC7A5 (0.40) | SLC7A5ALDH1A1MAPTPTGS1DPP4 | |
| SCHEMBL23651537 | 0.84 | SLC7A5 (0.40) | SLC7A5ALDH1A1MAPTPTGS1DPP4 | |
| SCHEMBL20830304 | 0.82 | SLC7A5 (0.35) | SLC7A5 | |
| SCHEMBL25015391 | 0.81 | SLC7A5 (0.36) | SLC7A5ALDH1A1MAPTPTGS1DPP4 | |
| SCHEMBL17789296 | 0.81 | SLC7A5 (0.36) | SLC7A5ALDH1A1MAPTPTGS1DPP4 | |
| SCHEMBL25015389 | 0.81 | SLC7A5 (0.36) | SLC7A5ALDH1A1MAPTPTGS1DPP4 | |
| SCHEMBL24782023 | 0.81 | SLC7A5 (0.48) | SLC7A5ALDH1A1MAPTPTGS1DPP4 | |
| SCHEMBL19523358 | 0.81 | SLC7A5 (0.36) | SLC7A5ALDH1A1MAPTPTGS1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348493-A1 | COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | BEIJING GREATWAY PHARMACEUTICAL TECHNOLOGY CO. LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348493-A1 | COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | BEIJING GREATWAY PHARMACEUTICAL TECHNOLOGY CO. LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230287009-A1 | OXO-SUBSTITUTED COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-11702431-B2 | Oxo-substituted compound | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-18 | — | — | US | disclosed |
| US-11702431-B2 | Oxo-substituted compound | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-18 | — | — | US | disclosed |
| US-20230158102-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTION | PHARMA MAR, S.A. (ES) | 2023-05-25 | — | — | US | disclosed |
| US-20230158104-A1 | COMPOUNDS FOR USE IN AUTOIMMUNE CONDITIONS | PHARMA MAR, S.A. (ES) | 2023-05-25 | — | — | US | disclosed |
| US-20230158104-A1 | COMPOUNDS FOR USE IN AUTOIMMUNE CONDITIONS | PHARMA MAR, S.A. (ES) | 2023-05-25 | — | — | US | disclosed |
| US-20230159594-A1 | COMPOUNDS FOR USE IN VIRAL INFECTIONS | PHARMA MAR, S.A. (ES) | 2023-05-25 | — | — | US | disclosed |
| US-20230159594-A1 | COMPOUNDS FOR USE IN VIRAL INFECTIONS | PHARMA MAR, S.A. (ES) | 2023-05-25 | — | — | US | disclosed |
| US-20110306586-A1 | NMDA Receptor Modulators and Uses Thereof | NAUREX, INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110286962-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. | 2011-11-24 | — | — | US | disclosed |
| US-7951789-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7902202-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20090238790-A2 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | IDENIX PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-7582649-B2 | Oral administration of a dosage of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one and a carrier; opiod receptor-like-1 G-protein coupled receptor inhibitors; psychological disorders; nervous system disorders; antidiabetic agents | JANSSEN PHARMACEUTICA, NV (BE) | 2009-09-01 | — | — | US | disclosed |
| US-20090169504-A1 | Compounds and Pharmaceutical compositions for the treatment of Viral infections | IDENIX PHARMACEUTICALS, INC | 2009-07-02 | — | — | US | disclosed |
| US-20090124614-A1 | HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | BATTISTA KATHLEEN | 2009-05-14 | — | — | US | disclosed |
| US-20090124614-A1 | HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | BATTISTA KATHLEEN | 2009-05-14 | — | — | US | disclosed |
| US-20080286230-A1 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348493-A1 | COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | GRIN1, GRIN3A, GRIN2C | SLC7A5 1146/4885ALDH1A1 3847/4885MAPT 298/4885 |
| US-11702431-B2 | Oxo-substituted compound | CYP51A1, OXA1L, O60361 | SLC7A5 456/4885ALDH1A1 473/4885MAPT 4495/4885 |
| US-20090169504-A1 | Compounds and Pharmaceutical compositions for the treatment of Viral infections | HAVCR2, PYGL, GYS2 | SLC7A5 2473/4885ALDH1A1 2922/4885MAPT 2374/4885 |
| US-20230158102-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTION | ACE, SARS1, ACE2 | SLC7A5 1120/4885ALDH1A1 1809/4885MAPT 3912/4885 |
| US-20230159594-A1 | COMPOUNDS FOR USE IN VIRAL INFECTIONS | OAT, MAVS, HAVCR2 | SLC7A5 1603/4885ALDH1A1 607/4885MAPT 380/4885 |
| US-20080286230-A1 | Compounds and pharmaceutical compositions for the treatment of viral infections | HAVCR2, PYGL, GYS2 | SLC7A5 2473/4885ALDH1A1 2922/4885MAPT 2374/4885 |
| US-20090238790-A2 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | HAVCR2, PYGL, GYS2 | SLC7A5 2473/4885ALDH1A1 2922/4885MAPT 2374/4885 |
| US-20110306586-A1 | NMDA Receptor Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | SLC7A5 838/4885ALDH1A1 3594/4885MAPT 737/4885 |
| US-20090124614-A1 | HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | OPRL1, ADRA1D, OPRD1 | SLC7A5 3178/4885ALDH1A1 175/4885MAPT 167/4885 |
| US-20230158104-A1 | COMPOUNDS FOR USE IN AUTOIMMUNE CONDITIONS | SSB, HLA-DRB1, TPMT | SLC7A5 2637/4885ALDH1A1 205/4885MAPT 2479/4885 |
| US-20230287009-A1 | OXO-SUBSTITUTED COMPOUND | CYP51A1, OXA1L, O60361 | SLC7A5 456/4885ALDH1A1 473/4885MAPT 4495/4885 |
| US-20110286962-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, PYGL, GYS2 | SLC7A5 2473/4885ALDH1A1 2922/4885MAPT 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.